KPX Lifescience.Co.Ltd
KPX Lifescience.Co.,Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals, pesticides, and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, an intermediate for piperacillin-based antibiotics, including N,N… Read more
KPX Lifescience.Co.Ltd (114450) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.095x
Based on the latest financial reports, KPX Lifescience.Co.Ltd (114450) has a cash flow conversion efficiency ratio of 0.095x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩3.33 Billion) by net assets (₩35.13 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
KPX Lifescience.Co.Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how KPX Lifescience.Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
KPX Lifescience.Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of KPX Lifescience.Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MIMDF
OTCQB:MIMDF
|
N/A |
|
Western Alaska Minerals Corp
PINK:WAMFF
|
-0.417x |
|
YSP Southeast Asia Holding Bhd
KLSE:7178
|
0.082x |
|
Soluna Holdings Inc
NASDAQ:SLNH
|
-0.030x |
|
ENEFIT GREEN AS
F:I6B
|
0.056x |
|
Tanaka Co.Ltd
F:TDJ
|
N/A |
|
BII Railway Transportation Technology Holdings Company Limited
F:CN6
|
-0.009x |
|
Dexelance S.p.A.
F:QZ2
|
-0.085x |
Annual Cash Flow Conversion Efficiency for KPX Lifescience.Co.Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of KPX Lifescience.Co.Ltd from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩35.75 Billion | ₩525.49 Million | 0.015x | +42.84% |
| 2023-12-31 | ₩35.95 Billion | ₩370.02 Million | 0.010x | +111.90% |
| 2022-12-31 | ₩52.64 Billion | ₩-4.55 Billion | -0.086x | -896.27% |
| 2021-12-31 | ₩56.30 Billion | ₩611.38 Million | 0.011x | -66.11% |
| 2020-12-31 | ₩59.37 Billion | ₩1.90 Billion | 0.032x | -54.41% |
| 2019-12-31 | ₩60.36 Billion | ₩4.24 Billion | 0.070x | -22.75% |
| 2018-12-31 | ₩59.11 Billion | ₩5.38 Billion | 0.091x | -0.57% |
| 2017-12-31 | ₩62.09 Billion | ₩5.68 Billion | 0.091x | -20.17% |
| 2016-12-31 | ₩61.66 Billion | ₩7.07 Billion | 0.115x | +16.09% |
| 2015-12-31 | ₩56.90 Billion | ₩5.62 Billion | 0.099x | +24.53% |
| 2014-12-31 | ₩51.53 Billion | ₩4.09 Billion | 0.079x | -- |